Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$176.94 ▼ -11.70
(-6.20%)
MKT CAP: $10.69B • VOL: 4.47M
52W L $101 52W H $199
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$149
MEDIAN
$198
MEAN
$202
HIGH
$241
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE RGEN TAPE
RGEN // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $214.10 | $203.48 | 2025-02-14 | $161.02 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $222.94 | $208.79 | 2025-02-06 | $166.32 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $201.71 | $194.63 | 2025-01-29 | $169.86 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $180.48 | — | 2025-01-17 | $173.40 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $155.71 | $168.09 | 2025-01-09 | $157.48 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $210.56 | $184.02 | 2024-12-18 | $153.94 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $171.63 | $178.71 | 2024-12-04 | $164.55 | -4.3% | 48% | C |